Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Neuropharmacology. 2012 Sep 13;65:134–142. doi: 10.1016/j.neuropharm.2012.09.004

Figure 6. WD dependent alterations of vesicle proteins during WD.

Figure 6

A, B) Protein expression of Synaptotagmin I [CON, 100.00 ± 4.72, n = 8; CIE, 87.47 ± 4.56, n = 9; WD, 98.11 ± 4.51, n = 8] and II [CON, 100.00 ± 8.83, n = 4; CIE, 108.38 ± 17.33; n = 5; WD, 97.73 ± 7.33, n = 4] are unaltered following WD. C) VAMP1 protein expression is unaltered by CIE or WD [100.00 ± 6.16, n = 12; CIE, 88.99 ± 4.17, n = 12; WD, 86.44 ± 4.61, n = 12]. D) WD but not CIE increases VAMP2 protein expression [CONE, 100.00 ± 7.33, n = 11; CIE, 96.70 ± 4.48, n = 12; WD, 125.68 ± 7.96, n = 12]. E, F) VGlut protein expression increases during both CIE and WD VGlut1: [CON, 100.00 ± 10.48, n = 8; CIE, 157.56 ± 15.31, n = 9; WD, 168.98 ± 17.83, n = 9; F(2,23) = 5.697, p < 0.05 * indicates significant difference from CON]; VGlut2: [CON, 100.00 ± 8.74, n = 8; CIE, 140.24 ± 10.80, n = 9; WD, 154.32 ± 10.82, n = 9; F(2,23) = 7.226, p < 0.05 * indicates significant difference from CON)]. Increased protein expression of vesicle associated protein suggest in increase in vesicle size or number. VAMP2 and VGlut2 protein data suggests a pathway specific increase in synaptic vesicles.